NCT03723148Available不适用
Compassionate Use of Fedratinib for Patients Who Have Previously Received TG101348, SAR302503 or Fedratinib
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
- Celgene
- 试验地点
- 1
研究概览
简要总结
This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib.
Expanded access is only available in markets where fedratinib is not yet approved.
详细描述
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects will be considered if they received TG101348, SAR302503 or Fedratinib as a participant on a clinical trial prior to 31 Jan 2018.
排除标准
- •Subject is eligible for enrollment in an ongoing clinical trial using Fedratinib or has been treated with Fedratinib after 31 Jan 2018.
研究者
研究点 (1)
Loading locations...
相似试验
Approved For Marketing
不适用
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment OptionsAdvanced Cancers and FGFR Genetic AlterationsNCT03825484Janssen Scientific Affairs, LLC
No Longer Available
不适用
Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)Colorectal CancerNCT06195514Takeda
No Longer Available
不适用
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From CerdulatinibRelapsed/Refractory Chronic Lymphocytic LeukemiaNon-hodgkin's LymphomaNCT04757259Alexion Pharmaceuticals, Inc.
Available
不适用
Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataNCT04159597AbbVie
Available
不适用
Expanded Access for ATB200/AT2221 for the Treatment of Pompe DiseasePompe DiseaseNCT03865836Amicus Therapeutics